JP2020514359A5 - - Google Patents

Download PDF

Info

Publication number
JP2020514359A5
JP2020514359A5 JP2019550634A JP2019550634A JP2020514359A5 JP 2020514359 A5 JP2020514359 A5 JP 2020514359A5 JP 2019550634 A JP2019550634 A JP 2019550634A JP 2019550634 A JP2019550634 A JP 2019550634A JP 2020514359 A5 JP2020514359 A5 JP 2020514359A5
Authority
JP
Japan
Prior art keywords
composition
cancer
nanoparticles
skin
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019550634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514359A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/022540 external-priority patent/WO2018170196A1/en
Publication of JP2020514359A publication Critical patent/JP2020514359A/ja
Publication of JP2020514359A5 publication Critical patent/JP2020514359A5/ja
Priority to JP2023103829A priority Critical patent/JP2023120393A/ja
Pending legal-status Critical Current

Links

JP2019550634A 2017-03-15 2018-03-15 タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法 Pending JP2020514359A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023103829A JP2023120393A (ja) 2017-03-15 2023-06-26 タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471561P 2017-03-15 2017-03-15
US62/471,561 2017-03-15
PCT/US2018/022540 WO2018170196A1 (en) 2017-03-15 2018-03-15 Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023103829A Division JP2023120393A (ja) 2017-03-15 2023-06-26 タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法

Publications (2)

Publication Number Publication Date
JP2020514359A JP2020514359A (ja) 2020-05-21
JP2020514359A5 true JP2020514359A5 (https=) 2021-04-08

Family

ID=61911679

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019550634A Pending JP2020514359A (ja) 2017-03-15 2018-03-15 タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法
JP2023103829A Pending JP2023120393A (ja) 2017-03-15 2023-06-26 タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023103829A Pending JP2023120393A (ja) 2017-03-15 2023-06-26 タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法

Country Status (8)

Country Link
US (4) US10555898B2 (https=)
EP (1) EP3595633B1 (https=)
JP (2) JP2020514359A (https=)
KR (1) KR102658256B1 (https=)
CN (2) CN118948828A (https=)
CA (1) CA3056395C (https=)
ES (1) ES2955884T3 (https=)
WO (1) WO2018170196A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026454C (en) 2015-06-04 2023-07-04 Crititech, Inc. Collection device and methods for use
ES3055492T3 (en) 2015-09-16 2026-02-12 Dfb Soria Llc Delivery of drug nanoparticles and methods of use thereof
EP3854381A1 (en) 2016-04-04 2021-07-28 Crititech, Inc. Methods for solid tumor treatment
WO2018170196A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
WO2018231908A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
KR20250057947A (ko) 2017-10-03 2025-04-29 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
EP3765035A4 (en) 2018-03-16 2021-10-27 DFB Soria, LLC TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND COLD CANCER USING TAXANE NANOPARTICLES
WO2019231499A1 (en) * 2018-05-31 2019-12-05 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for treatment of cancer
US20220273530A1 (en) * 2019-08-29 2022-09-01 Skinosive Bioadhesive particles comprising active agents, and uses thereof
EP4034087A4 (en) 2019-09-23 2023-10-25 DDS Research Inc. LIPID VESICLE COMPOSITIONS USING PENETRATION ENHANCING AGENTS
WO2022204305A2 (en) 2021-03-24 2022-09-29 Glo Pharma, Inc. Peptides and methods for reducing skin pigmentation
CN120818186B (zh) * 2025-09-12 2025-11-18 四川大学 一种基于深共晶体系的聚轮烷材料及其制备方法和应用

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
CA2472404A1 (en) 1993-07-19 1995-02-02 Angiotech Pharmaceuticals, Inc. Combination of stent and anti-angiogenic factor
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
DE69734060T2 (de) 1996-05-24 2006-06-29 Angiotech Pharmaceuticals, Inc., Vancouver Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
US5756537A (en) 1996-11-08 1998-05-26 Parkash S. Gill, M.D., Inc. Regime for paclitaxel in Kaposi's sarcoma patients
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
PT1023050E (pt) 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6113795A (en) 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
IN191203B (https=) 1999-02-17 2003-10-04 Amarnath Prof Maitra
US6365191B1 (en) 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof
US6406722B1 (en) 1999-02-18 2002-06-18 Robert G. Gallaher Method of treating viral infections and lesions with taxane compounds
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
NZ516083A (en) 1999-05-27 2003-08-29 Acusphere Inc Porous drug matrices and methods of manufacture thereof
US6892091B1 (en) 2000-02-18 2005-05-10 Biosense, Inc. Catheter, method and apparatus for generating an electrical map of a chamber of the heart
CA2410632A1 (en) 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
US20040022862A1 (en) 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
EP1427366A2 (en) 2001-08-29 2004-06-16 UMD, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
CN1592607A (zh) 2001-10-15 2005-03-09 克里蒂泰克公司 水溶性差药物的组合物、其给药方法和治疗方法
WO2003080027A1 (en) 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
WO2004098570A1 (en) 2002-10-30 2004-11-18 Spherics, Inc. Nanoparticulate bioactive agents
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
FR2856301B1 (fr) 2003-06-23 2007-08-03 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
WO2005039533A1 (en) 2003-10-15 2005-05-06 Medigene Ag Method of administering cationic liposomes comprising an active drug
EP1686962B9 (en) 2003-11-05 2012-10-03 Elan Pharma International Limited Nanoparticulate compositions having a peptide as a surface stabilizer
FR2862540B1 (fr) 2003-11-21 2007-03-30 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
FR2871695B1 (fr) 2004-06-17 2008-07-04 Galderma Sa Composition pharmaceutique comprenant un agent silicone et deux principes actifs solubilises
FR2871697B1 (fr) 2004-06-17 2007-06-29 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile
US7361683B2 (en) 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
US8062658B2 (en) 2004-12-14 2011-11-22 Poly-Med, Inc. Multicomponent bioactive intravaginal ring
JP2008531591A (ja) 2005-02-24 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド ドセタキセルおよびそれらの類似体のナノ粒子製剤
CN101151028A (zh) * 2005-03-03 2008-03-26 Isw集团公司 局部用凝胶组合物
GB0506139D0 (en) 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
CA2609927A1 (en) 2005-04-27 2006-11-02 Leiden University Medical Center Methods and means for the treatment of hpv induced intraepithelial neoplasias
US20090304803A1 (en) 2005-06-06 2009-12-10 The General Hospital Corporation Compositions and methods relating to target-specific photodynamic therapy
EP3527202A1 (en) 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
RU2008128451A (ru) 2005-12-14 2010-01-20 Огенодженесис, Инк. (US) Композиция для лечения и ухода за кожей, способ ее получения, способ ее использования
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
US8343962B2 (en) 2006-03-06 2013-01-01 Nuvo Research Inc. Topical formulation
US7744923B2 (en) 2006-10-11 2010-06-29 Crititech, Inc. Method for precipitation of small medicament particles into use containers
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
CA2611803C (en) 2006-11-22 2013-03-19 Bj Services Company Well treatment fluid containing viscoelastic surfactant and viscosification activator
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
TWI405590B (zh) 2007-04-06 2013-08-21 活效製藥股份有限公司 微粉碎化有機化合物粒子之製法
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス, エルエルシー 再発性癌の処置のための方法および組成物
ITMI20071267A1 (it) 2007-06-22 2008-12-23 Fidia Farmaceutici Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative
HU227970B1 (en) 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
GB0716591D0 (en) * 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
CN101129338A (zh) 2007-08-27 2008-02-27 四川大学 超临界流体新技术微细化抗癌药物紫杉醇
DK2200588T3 (da) 2007-09-25 2019-07-01 Solubest Ltd Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
EP2222278B1 (en) 2007-11-28 2015-04-08 Celator Pharmaceuticals, Inc. Improved taxane delivery system
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8865194B1 (en) 2007-12-20 2014-10-21 Theraplex Company, LLC Reducing tackiness and greasiness of petrolatum-like materials
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US8952075B2 (en) 2008-05-22 2015-02-10 Poly-Med, Inc. Bioactive polymeric liquid formulations of absorbable, segmented aliphatic polyurethane compositions
WO2009153774A2 (en) 2008-06-17 2009-12-23 Rosetta Genomics Ltd. Compositions and methods for prognosis of ovarian cancer
KR101848095B1 (ko) 2008-06-26 2018-04-11 안테리오스, 인코퍼레이티드 경피 운반
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
GB2474930B (en) * 2009-10-02 2012-07-04 Foamix Ltd Topical tetracycline compositions
WO2011064631A1 (en) 2009-10-02 2011-06-03 Foamix Ltd. Surfactant-free, water-free, foamable compositions and breakable foams and their uses
CA2777397C (en) 2009-10-13 2017-08-29 Rexahn Pharmaceuticals, Inc. Polymeric systems for the delivery of anticancer agents
CN101829061A (zh) 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
CN101843582B (zh) 2010-05-18 2011-12-21 南京工业大学 紫杉醇纳米混悬剂及其制备方法
WO2011151418A2 (en) 2010-06-02 2011-12-08 Abbott Gmbh & Co. Kg Nanosusupension formulation comprising a polydimethylsiloxane hydrophobic phase
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
WO2012013229A1 (en) 2010-07-28 2012-02-02 Fondazione Irccs Therapeutic agent, composition including said agent, implantable device and process for the treatment of cervical cancer and/or for the prevention of the formation of neoplasms in correspondence of the cervix in a human female genital system.
WO2012017349A2 (en) 2010-08-02 2012-02-09 Ranbaxy Laboratories Limited An improved topical pharmaceutical composition comprising nanonized silver sulfadiazine
US8563535B2 (en) 2011-03-29 2013-10-22 Kamal Mehta Combination composition comprising benzoyl peroxide and adapalene
WO2012130314A1 (en) 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
WO2012135422A2 (en) 2011-04-01 2012-10-04 University Of Florida Research Foundation, Inc. Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics
AU2012251135A1 (en) 2011-05-02 2013-11-07 Lipidor Ab Treatment of psoriasis
BR112013033466A8 (pt) 2011-06-27 2018-03-06 Cristal Delivery B V uso de um sistema de liberação controlada e sistema de liberação controlada
US20130337070A1 (en) * 2012-05-25 2013-12-19 University Of Central Florida Research Foundation Inc. Coated Nanoparticle Therapy for Skin Cancer
US9018246B2 (en) 2012-09-05 2015-04-28 Lp Pharmaceutical (Xiamen) Co., Ltd. Transmucosal administration of taxanes
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
JP2014114249A (ja) 2012-12-11 2014-06-26 Kanae Technos:Kk 基剤、及び皮膚外用剤
GB2511115A (en) * 2013-02-25 2014-08-27 Linde Ag An end port regenerative furnace
US8778181B1 (en) 2013-03-14 2014-07-15 Crititech, Inc. Equipment assembly for and method of processing particles
EP2978420A4 (en) 2013-03-28 2016-12-21 Bbs Nanotechnology Ltd STABLE NANO COMPOSITION WITH DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
AU2014302215A1 (en) 2013-06-28 2016-01-21 Pfizer Inc. Docetaxel polymeric nanoparticles for cancer treatment
TWI601542B (zh) 2014-04-18 2017-10-11 林信湧 一種用於治療肺癌之吸入式醫藥組成物及其備製方法
US20150342872A1 (en) 2014-06-01 2015-12-03 Crititech, Inc. Use of Paclitaxel Particles
WO2016071365A1 (en) 2014-11-03 2016-05-12 Spherium Biomed, S.L. Topical pharmaceutical compositions of paclitaxel
CN105280869B (zh) 2015-01-07 2018-07-31 保定钰鑫电气科技有限公司 一种组合式蓄电池端子连接片
CA3026454C (en) 2015-06-04 2023-07-04 Crititech, Inc. Collection device and methods for use
ES3055492T3 (en) 2015-09-16 2026-02-12 Dfb Soria Llc Delivery of drug nanoparticles and methods of use thereof
CN105380869A (zh) * 2015-12-28 2016-03-09 深圳中农科工创业资产管理有限公司 一种纳米红豆杉护肤品及其用途
EP3854381A1 (en) 2016-04-04 2021-07-28 Crititech, Inc. Methods for solid tumor treatment
WO2018170196A1 (en) * 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes

Similar Documents

Publication Publication Date Title
JP2020514359A5 (https=)
JP2023120393A5 (https=)
JP2018531231A5 (https=)
JP2011246704A5 (https=)
Wang et al. Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents
JP2013531621A5 (https=)
Mikhailov Synthesis of 3d-element metalmacrocyclic chelates into polypeptide biopolymer medium and their molecular structures
WO2011119354A3 (en) Nanoparticle-densified completion fluids
CN113366008A (zh) 一种cd73抑制剂,其制备方法和应用
RU2017119820A (ru) Композиции и способы профилактики и лечения злокачественных новообразований
JP2015224221A5 (https=)
JP2011506257A5 (https=)
RU2020110399A (ru) Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака
JP2019534865A5 (https=)
WO2018131430A1 (ja) 金属元素含有ナノ粒子を用いたヒドロシリル化による有機ケイ素化合物の製造方法
JP2021517906A5 (https=)
JP2015129103A (ja) 有機シラン化合物の製造方法及び有機シラン化合物合成用触媒組成物
JP2013518032A5 (https=)
Hamacher Recorded accounts of meteoritic events in the oral traditions of Indigenous Australians
JP2018168261A5 (https=)
JP2021518362A5 (https=)
Prez et al. Crystal structure of bis [4-(1H-pyrrol-1-yl) phenyl] ferrocene-1, 1′-dicarboxylate: a potential chemotherapeutic drug
TUKIRAN et al. CHEMICAL PROFILING ETHYL ACETATE EXTRACT OF BASILICUM POLYSTACHYON LEAVES AND EXPLORATION OF ANTICANCER SIRT1 INHIBITORS USING IN SILICO APPROACH
TR201814012A2 (tr) Suda çözünebilen, agregasyon göstermeyen akciğer, karaciğer, meme ve melanoma kanser türlerine karşı ın vıtro antikanser etkili yeni bir silisyum ftalosiyanin bileşiği.
Mufazalov et al. POSTOPERATIVE RADIOTHERAPY OF NON-SMALL CELL LUNG CANCER